Cell line · CVCL_0526
Papers161
1 to 20 of 161
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Berberine and Etoposide Exert Synergistic Anticancer Effects in A431 Epidermoid Carcinoma Cells. | ACS Omega | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Genotype-driven tumor ecosystems drive immune evasion and immunotherapy resistance in melanoma. | Mol Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Recombinant BaMtx Preserves the Biological Properties of a Lys49 Phospholipase A2 from Bothrops atrox and Reveals Differential Responses in Tumor and Non-Tumor Cell Models. | Toxins (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Hallachrome, a marine anthraquinone, impairs cell proliferation by acting as a functional mitochondrial uncoupler in A375 melanoma cells. | Front Pharmacol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Metabolic buffering restricts phenotype switching in melanoma. | EMBO J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Driver Mutation Subtypes Differentially Shape Immune Evasion Landscapes in Melanoma: An AI-Driven Inflammatory Pathway Model Implicating CCNE1. | Hum Mutat | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MITF maintains genome stability in nonmelanocyte lineages. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Loss of AMBRA1 activates MAPK and angiogenesis signaling pathways in melanoma cells. | FEBS Open Bio | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Global analysis of cancer cell responses to USP9X inhibition. | EMBO J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Proteasomal degradation of intracellularly expressed Amblyomin-X limits suicide gene therapy potential in melanoma cells. | FEBS Open Bio | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Enhancing Proteasome Activity in T Cells Alleviates Exhaustion and Improves Antitumor Immunity. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| AhR-dependent ferroptosis as a therapeutic opportunity to counteract BRAFi-resistance in melanoma. | Cell Death Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| BGN/MDK Axis in the Melanoma Tumor Microenvironment Strengthens Tumor Malignancy by Modulating Cancer Cells and Cancer-Associated Fibroblasts Crosstalk. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Bioinformatics and Wet-Lab-Based Pipeline Identifies CLDN10 and GJB2 as Epigenetically Silenced Tumor Suppressor Genes in Cutaneous Melanoma. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| αvβ3 CAR-T Cells Simultaneously Targeting Tumor and Metastases Produce Highly Effective Control in Preclinical Models of Melanoma and Triple-Negative Breast Cancer. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Dysregulation of the PATZ1/CTCF Balance Silences ZBTB20 to Drive Melanoma Progression. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The lipid-metabolic enzyme HSD17B12 drives lysosomal degradation of PD-L1 potentiating anti-tumor immunity in a mouse model. | PLoS Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The neural crest-associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0526/papers